Astellas Transfers Compounds To DNDi For Drug Discovery In Chagas, Leishmaniasis and Sleeping Sickness
This article was originally published in PharmAsia News
Executive Summary
Astellas and other Japanese pharma have become more open to new partnerships that expand drug access, as well as their market footprint.
You may also be interested in...
Can Emerging Markets Fuel Growth And Restore Trust In Pharma?
When looking at emerging markets, most biopharma analysts focus on commercial opportunities - whether "pharmerging" markets will help mitigate lost sales in the U.S. and Europe stemming from the patent cliff, increasing pressure from payers and related challenges
GSK's Sandy Macrae On R&D For Emerging Markets: An Interview With PharmAsia News (Part 2 of 2)
GlaxoSmithKline R&D Chairman Moncef Slaoui tasked Sandy Macrae in 2008 to put together a group that would make sure GSK focused some of its R&D efforts on the needs of Asia Pacific and emerging markets. Since then, GSK's APJEM R&D - Asia Pacific, Japan, and Emerging Markets - has been busy pitching the company's established presence in emerging markets to companies looking to expand beyond traditional markets, and even some that aren't. Macrae's lean eight-person team has, in its approach to companies, said that while GSK is looking for later-stage molecules, the group is not opposed to licensing a compound for Asia while its partners pursue Western deals with another company (PharmAsia News, April 9, 2009).
Eisai Opens Fourth Knowledge Center In India As Launch Pad For Next-generation Global Products; Focus On Affordability
Sitting on a 50-acre campus at Southern India's Jawaharlal Nehru Pharma City, Eisai's newly minted Knowledge Center India is the company's first integrated facility that includes API production and research functions in one site, bringing the company one step further toward creating a global supply and research hub